Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘American Heart Association’ Category

A shadow was cast on a bone researcher’s work. What are journals doing about his papers?

with one comment

Last year, a researcher cast doubt on a bone scientist’s clinical trials, suggesting some of the findings may not be legitimate. So what’s happened since?

Since 2015, journals have retracted 14 papers by bone researcher Yoshihiro Sato, based at Mitate Hospital in Japan, for issues ranging from self-plagiarism, to problems with data, to including co-authors without their consent. (We covered the latest two retractions this week.) Last year’s analysis identified patterns in more than 30 of Sato’s clinical trials that suggest systematic problems with the results. (Sato has defended his research.)

With doubts cast on Sato’s body of work, we contacted the journals that have published his papers involving human trials, to see if any taken another look at Sato’s work; several responded. While most believe there is little reason to take further action at this time, some told us they are investigating.
Read the rest of this entry »

Author lifts from one paper in two different articles. Why does one journal retract, while the other corrects?

with 4 comments

circ resAre there instances when similarities between papers should be fixed by a correction, rather than a retraction?

We’re asking ourselves that question after seeing two journals take very different approaches to a somewhat similar situation. Last year, Frontiers in Physiology retracted a paper by Anastasios Lymperopoulos at Nova Southeastern University in Florida because of an “an unacceptable level of similarity” to a 2009 review article by different authors. But more recently, after Circulation Research discovered another paper co-authored by Lymperopoulos also contained similar text from the same 2009 review, it decided to correct the passages.

The last author of the Circulation Research paper told us the overlap between the two papers was less than 5%, and the journal never suggested the authors retract the paper.

Here’s the correction notice in Circulation Research:

Read the rest of this entry »

Vector wasn’t a gift after all, correction notes

without comments

CirculationA paper accidentally credited the wrong researcher with providing part of an experiment.

It turns out that one of the authors supplied an expression vector to a Circulation paper about the molecular underpinnings of atherosclerosis — not the outside researcher originally thanked in the acknowledgements section.

The correction notice to the paper makes the situation sound more mysterious than it appears to be:

Read the rest of this entry »

Author “committed serious mistakes,” finds Taipei investigation

without comments

Arteriosclerosis Thrombosis and Vascular BiologyAn investigation at Taipei Medical University found that an author made “serious mistakes” when preparing a manuscript.

The journal prompted the university to investigate the paper, which looks at the role of a protein in repairing arteries after an injury.

The retraction notice explains:

Read the rest of this entry »

Raw files help fix 2003 figure by heart researcher accused of fraud

with 2 comments


A researcher accused of misconduct by an anonymous Japanese blogger has corrected a 2003 paper in Circulation Research, after providing a university investigation with the original source files.

Allegations of fraud have dogged Shokei Kim-Mitsuyama for years, and even caused him to step down from his position as editor in chief at another journal. However, Kim-Mitsuyama and his colleagues call the latest correction a “mistake,” which didn’t affect any of the paper’s conclusions.

We’ve unearthed a total of five publications co-authored by Kim-Mitsuyama that have earned corrections, the latest of which cites an investigation by the university:

Read the rest of this entry »

Biologist’s research under investigation in Sweden after being questioned on PubPeer

with 9 comments


Suchitra Sumitran-Holgersson

The University of Gothenburg in Sweden is investigating several papers co-authored by biologist Suchitra Sumitran-Holgersson after they were challenged on PubPeer.

Sumitran-Holgersson already has one retraction under her belt — of a 2005 Blood paper, after another investigation concluded the results “cannot be considered reliable.” Sumitran-Holgersson and her husband, co-author Jan Holgersson, did not sign the retraction notice. Both were based at the Karolinska Institutet (KI) at the time, but have since moved to the University of Gothenburg.

Now, the University of Gothenburg has launched its own investigation of the papers questioned on PubPeer, according to Read the rest of this entry »

8th retraction appears for researcher who faked patient records

with one comment

S00219150An 8th paper has been retracted for Anna Ahimastos, a heart researcher who faked patient records.

It’s the last in a chain of retractions that were the result of an investigation by her former workplace, Baker IDI Heart & Diabetes Institute in Australia. As with the others, she did not agree to the retraction.

The investigation found fabricated patients records in some papers; in other papers, such as the newly retracted 2010 study in Atherosclerosis, the original data source could not be verified.  The latest retraction — “A role for plasma transforming growth factor-β and matrix metalloproteinases in aortic aneurysm surveillance in Marfan syndrome?” — followed up on a previous clinical trial, examining how a blood pressure drug might help patients with a life-threatening genetic disorder.

That previous trial — which also included 17 patients with Marfan syndrome treated with either placebo or perindopril — has been retracted from JAMA; the New England Journal of Medicine has also retracted a related letter.

The latest retraction note conveys similar information to the other perindopril/Marfan syndrome retractions: Read the rest of this entry »

Investigation prompts 5th retraction for cancer researcher for “unresolvable concerns”

with 6 comments

3.coverAn investigation at the University of New South Wales in Australia has led to a fifth retraction for a cancer researcher long accused of misconduct, due to “unresolvable concerns” with some images.

As we reported in December, UNSW cleared Levon Khachigian of misconduct, concluding that his previous issues stemmed from “genuine error or honest oversight.” Now, Circulation Research is retracting one of his papers after an investigation commissioned by UNSW was unable to find electronic records for two similar images from a 2009 paper, nor records of the images in original lab books.

Again, the retraction note affirms that this is not a sign of misconduct:

UNSW has not attributed any instance of research misconduct or responsibility for the unavailability of the original data to Professor Khachigian or to any of the authors of the publication.

Here’s the retraction note in full for “Angiotensin II-Inducible Smooth Muscle Cell Apoptosis Involves the Angiotensin II Type 2 Receptor, GATA-6 Activation, and FasL-Fas Engagement:” Read the rest of this entry »

Stem cell researcher that sued Harvard failed to disclose conflicts on 6 publications

with 2 comments

Piero Anversa, a stem cell researcher who we recently learned is leaving Harvard and Brigham & Women’s Hospital after suing them, has added a disclosure statement to six publications.

The four papers and two letters were published in Circulation, and all bear identical corrections:

Piero Anversa, MD, discloses that he is a member of Analogous, LLC.

The author regrets this omission.

Trouble is, we can’t find a company by that name. What we do know:

Read the rest of this entry »

7th retraction for heart researcher who faked patient records

with one comment

1.coverAnna Ahimastos, a heart researcher who faked patient records, has notched her 7th retraction.

One more paper is expected to be retracted, according to a spokesperson from her former institution, the Baker IDI Heart & Diabetes Institute in Australia.

As with the other retractions, the 2005 paper in Hypertension — about how the hypertension drug ramipril may help alleviate cardiovascular disease — is being pulled after Ahimastos admitted to scientific misconduct. She asserts the data remain valid, and has not signed the retraction notice.

The Hypertension paper has been cited 63 times, according to Thomson Scientific’s Web of Knowledge. Here’s the retraction note in full (the language will be familiar to readers who have been following this case):

Read the rest of this entry »